A5021467465- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Urologic and reproductive health conditions
- Urological Disorders and Treatments
- Urinary Bladder and Prostate Research
- Bladder and Urothelial Cancer Treatments
- Genital Health and Disease
- Testicular diseases and treatments
- Pediatric Urology and Nephrology Studies
- Immunotherapy and Immune Responses
- Pelvic floor disorders treatments
- Kidney Stones and Urolithiasis Treatments
- CAR-T cell therapy research
- Ureteral procedures and complications
- MRI in cancer diagnosis
- Sexual function and dysfunction studies
- Cancer Immunotherapy and Biomarkers
- Sarcoma Diagnosis and Treatment
- Pelvic and Acetabular Injuries
- Renal cell carcinoma treatment
- Ovarian cancer diagnosis and treatment
- Medical and Health Sciences Research
- COVID-19 and healthcare impacts
- Advanced X-ray and CT Imaging
- Renal and Vascular Pathologies
Ludwig-Maximilians-Universität München
2016-2025
LMU Klinikum
1980-2025
München Klinik
2025
Klinik und Poliklinik für Urologie
2021-2023
Center for Integrated Protein Science Munich
2014-2018
German Center for Lung Research
2016-2018
University of Fribourg
2014
Helmholtz Zentrum München
2014
Roche (Switzerland)
2014
University Hospital Cologne
2014
Adoptive T cell transfer (ACT) is currently under investigation for the treatment of metastatic cancer. Recent evidence suggests that coinhibitory PD-1-PD-L1 axis plays a major role in ACT failure. We hypothesized new fusion receptor reverting PD-1-mediated inhibition into CD28 costimulation may break peripheral tolerance.Different PD-1-CD28 constructs were created and retrovirally transduced primary transgenic murine CD8(+) cells specific ovalbumin (OT-1). Cytokine release, proliferation,...
Major urological guidelines do not currently recommend robot-assisted surgery compared with laparoscopic or open due to the lack of high-quality evidence. We aimed provide real-world data on evolution robotic urology and compare its perioperative outcomes those surgeries.
Human biofluids serve as indicators of various physiological states, and recent advances in molecular profiling technologies hold great potential for enhancing clinical diagnostics. Leveraging developments laser-based electric-field fingerprinting, we assess its vitro In a proof-of-concept study involving 2533 participants, conducted randomized measurement campaigns to spectroscopically profile bulk venous blood plasma across lung, prostate, breast, bladder cancer. Employing machine...
Purified protein vaccines often require adjuvants for efficient stimulation of immune responses. There is no licensed mucosal adjuvant on the market to adequately boost response purified antigens intranasal applications in humans. Bacterial outer membrane vesicles (OMV) are attractive candidates potentially combining antigenic and properties one substance. To more precisely characterize potential Escherichia coli OMV vaccination with heterologous antigens, responses AnAPN1 Pfs48/45 as well...
De novo oligometastatic prostate cancer (omPCa) on prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is a new disease entity and its optimal management remains unknown.
Modern risk stratification of prostate cancer (PCa) allows for prediction advanced disease with a high level certainty. We aimed to evaluate prospective series patients undergoing radical prostatectomy without prior biopsy based solely on clinical criteria and imaging results. The were divided into three groups. Group 1 included 27 with: (i) suspicious digital rectal examination, (ii) PSA ≥ 10 ng/mL, (iii) PI-RADS 4/5 mpMRI, (iv) suspicion PCa PSMA-PET. 2 six who fulfilled i, ii, iii but did...
Background:One bottleneck for adoptive T cell therapy (ACT) is recruitment of cells into tumors. We hypothesized that combining tumor-specific cells, modified with a marker antigen and bispecific antibody (BiAb) selectively recognizes transduced tumor would improve to tumors enhance therapeutic efficacy.
Real-world data exploring the perioperative outcomes of different surgical treatments for benign prostatic hyperplasia (BPH) are lacking. We aimed to assess trends BPH surgeries and compare their outcomes. used GeRmAn Nationwide inpatient Data (GRAND), provided by Research Center Federal Bureau Statistics (2005-2022), performed multiple patient-level analyses. Our study included 1 355 845 BPH. Of these, 084 650 (79.9%) were transurethral resection prostate (TURP), 90 735 (6.9%) simple...
Abstract Purpose Despite the high incidence of perioperative complications following cystectomy, there is a lack evidence regarding patients’ perceptions. Moreover, discrepancies between established complication grading systems and patient’s perspective remain unexplored. Methods We prospectively evaluated after cystectomy using Clavien-Dindo Classification (CDC) Comprehensive Complication Index (CCI). The CDC CCI were compared to patient-reported grades through Spearman correlation...
Background and Objective: The cost of imaging interventions in the surgical field varies between countries sometimes within different regions same country. Procedural takes into account equipment, consumables, operating room, surgical, anesthetic nursing teams, radiology, medications, hospital stay. Health care systems therefore face an incredible burden related to investigations procedures. aim this study was collect costs for kidney calculi across hospitals health world. Methods: An online...
Current evidence suggests that prior prostatic interventions, such as prostatectomy, radiation, or transurethral surgery may increase the risk of incontinence in patients undergoing radical cystectomy (RC) with ileal orthotopic neobladder reconstruction. We aimed to evaluate short- and long-term complications, functional outcomes reconstruction RC after procedures. analyzed who underwent intervention our department from 2013-2022. A comparison was made between receiving (ONB) versus conduit,...
Muscle-invasive bladder cancer (MIBC) represents a genetically heterogeneous disease with limited prognostic markers. This study aimed to validate the relevance of combined alterations in cell cycle regulators RB1, p53, and p21 broad cohort MIBC patients undergoing radical cystectomy (RC). We analyzed formalin-fixed paraffin-embedded material from who underwent RC at Department Urology, University Hospital, Ludwig-Maximilians-University Munich. Tissue microarrays (TMAs) 251 (pT2-pT4) were...
Objective To compare the perioperative complications of most common focal therapy (FT) modalities for prostate cancer. Patients and Methods We assessed GeRmAn Nationwide inpatient Data (GRAND) from 2005 to 2023, provided by Research Center Federal Bureau Statistics. compared outcomes high‐intensity focused ultrasound (HIFU), hyperthermia, irreversible electroporation prostate, cryotherapy, vascular photodynamic (VTP), transurethral ablation, as well HIFU vs non‐HIFU treatments in general....
Background: Interaction of the programmed death receptor 1 (PD-1) and its ligand, PD-L1, suppresses T cell activity permits tumors to evade cell-mediated immune surveillance. We have recently demonstrated that antigen-specific CD8+ cells transduced with a PD1-CD28 fusion protein are protected from PD-1-mediated inhibition. now investigated potential protein-transduced CD4+ alone or in combination for immunotherapy pancreatic cancer non-Hodgkin lymphoma. Methods: OVA-specific were...
Focal therapy (FT) of the prostate for low risk cancer (PCa) is an alternative to traditional definite treatment options like external beam radiotherapy or radical prostatectomy. However, follow up after FT still challenging and subject current studies. Significance imaging such as multiparametric MRI (mpMRI) currently not well established. In this study, we aimed evaluate efficacy during PCa treated with focal HIFU using CEUS image fusion.Retrospective single arm study in patients uni-...
Toll-like receptor 7 (TLR7) agonists are potent immune stimulants able to overcome cancer-associated suppression. Due dose-limiting systemic toxicities, only the topically applied TLR7 agonist (imiquimod) has been approved for therapy of skin tumors. There is a need TLR7-activating compounds with equivalent efficacy but less toxicity. SC1, novel small molecule TLR7, type-1 interferon inducer, comparable reference resiquimod, yet lower induction proinflammatory cytokines. In vivo, SC1...